AIM ImmunoTech Inc. has announced that it has received a warning notification from NYSE American LLC, indicating noncompliance with the minimum stockholders' equity requirements outlined in Sections 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide. As of March 31, 2025, AIM reported a stockholders' deficit of negative $3.9 million, alongside losses in its five most recent fiscal years. The company has until June 11, 2026, to regain compliance, following a previously accepted plan by NYSE American. The letter does not affect AIM's business operations or its trading, which continues under the symbol "AIM" on the NYSE American.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.